RH Impact responds to FDA’s announcement to postpone advisory committee meeting for over-the-counter birth control pill

November 03, 2022


Washington, D.C. November 2, 2022  – We are deeply disappointed by the FDA’s delay of the advisory committee meeting to discuss the application to move a progestin-only birth control pill over the counter (OTC). Every day we wait is another day longer where barriers remain in place preventing people from getting access to the care they need. It’s been more than 60 years since the FDA approved the first birth control pill in the U.S. There are decades of evidence and science showing that birth control pills are safe and effective for over-the-counter use. In the aftermath of the fall of Roe, there has never been a more crucial need to expand contraceptive access and bring birth control pills over the counter. The FDA must set a new date for an advisory committee immediately and commit to reviewing this historic application in a timely manner without delay. It’s past time for an over-the-counter birth control pill that’s fully covered by insurance, affordable, and available to people of all ages.